Shares Magazine
172.50p+1.50 (+0.88%)17 Apr 2025, 16:35
Jump to:
Hemogenyx Pharmaceuticals PLC Fundamentals
| Company Name | Hemogenyx Pharmaceuticals PLC | Last Updated | 2025-04-17 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 4.094 m | Market Cap | £7.06 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£2.40 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4552 | Debt Equity Ratio | 0.8253 |
| Asset Equity Ratio | 2.0230 | Cash Equity Ratio | 0.5433 |
| Quick Ratio | 4.3785 | Current Ratio | 4.38 |
| Price To Book Value | 2.3047 | ROCE | 0 |
Hemogenyx Pharmaceuticals PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Hemogenyx Pharmaceuticals PLC Company Financials
| Assets | 2023 | 2022 |
|---|---|---|
| Tangible Assets | £3.31 m | £3.92 m |
| Intangible Assets | £441,493.00 | £441,493.00 |
| Investments | 0 | 0 |
| Total Fixed Assets | £3.94 m | £4.50 m |
| Stocks | 0 | 0 |
| Debtors | £1,074.00 | £146.00 |
| Cash & Equivalents | £1.25 m | £2.53 m |
| Other Assets | 0 | 0 |
| Total Assets | £6.11 m | £7.09 m |
| Liabilities | 2023 | 2022 |
|---|---|---|
| Creditors within 1 year | £652,085.00 | £748,411.00 |
| Creditors after 1 year | £2.67 m | £3.10 m |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £3.32 m | £3.85 m |
| Net assets | £2.78 m | £3.24 m |
| Equity | 2023 | 2022 |
|---|---|---|
| Called up share capital | £11.76 m | £9.80 m |
| Share Premium | £19.94 m | £16.81 m |
| Profit / Loss | -£6.70 m | -£3.99 m |
| Other Equity | £2.82 m | £3.28 m |
| Preference & Minorities | -£37,723.00 | -£31,908.00 |
| Total Capital Employed | £2.78 m | £3.24 m |
| Ratios | 2023 | 2022 |
|---|---|---|
| Debt Ratio | £0.49 | £0.49 |
| Debt-to-Equity | £0.95 | £0.95 |
| Assets / Equity | 2.0230 | 2.0230 |
| Cash / Equity | 0.5433 | 0.5433 |
| EPS | -£2.40 | -£2.00 |
| Cash Flow | 2023 | 2022 |
|---|---|---|
| Cash from operating activities | -£6.11 m | -£2.91 m |
| Cashflow before financing | -£1.66 m | -£3.02 m |
| Increase in Cash | -£1.69 m | -£3.43 m |
| Income | 2023 | 2022 |
|---|---|---|
| Turnover | 0 | 0 |
| Cost of sales | £1.68 m | £2.20 m |
| Gross Profit | -£1.68 m | -£2.20 m |
| Operating Profit | -£6.47 m | -£4.00 m |
| Pre-Tax profit | -£6.70 m | -£3.99 m |
Hemogenyx Pharmaceuticals PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. |
| Latest Interim Date | 27 Sep 2024 |
| Latest Fiscal Year End Date | 25 Apr 2025 |
Hemogenyx Pharmaceuticals PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-12-13 | Mr. Peter Redmond | Non-Executive Director |
| 2017-10-05 | Mr. Geoffrey Gilbert Dart | Executive Director,Chairman |
| 2018-11-05 | Mr. Lawrence Pemble | Executive Director,Chief Operating Officer |
| 2018-04-03 | Mr. Adrian Richard Thorpe Beeston | Non-Executive Director |
| 2024-12-13 | Dr. Vladislav Sandler | Executive Director,Chief Executive Officer |
| 2024-12-13 | Ms. Alexis M. Sandler | Non-Executive Director |
| 2019-01-04 | Dr. Robin Campbell | Non-Executive Director |
| 2024-12-13 | Professor Sir. Marc Feldmann | Non-Executive Director,Chairman |
Hemogenyx Pharmaceuticals PLC Contact Details
| Company Name | Hemogenyx Pharmaceuticals PLC |
|---|---|
| Address | 5 Fleet Place, London, EC4M 7RD |
| Telephone | |
| Website | https://www.hemogenyx.com |
Hemogenyx Pharmaceuticals PLC Advisors
| Financial Adviser | Peterhouse Corporate Finance Ltd |
|---|---|
| Phone | +44 2074690930 |
| Fax | +44 2072209798 |
| Stockbroker | Optiva Securities Ltd |
|---|---|
| Phone | +44 2031371902 |
| Solicitor | Charles Russell Speechlys LLP |
|---|---|
| Phone | +44 2072035000 |
| Bank | Metro Bank Plc |
|---|
| Auditor | PKF Littlejohn |
|---|---|
| Phone | +44 2075162200 |
| Fax | +44 2075162400 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
| Financial PR Adviser | Camarco |
|---|---|
| Phone | +44 02037574980 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dunelm Group PLC | 1,074.00 | 13.29 |
| Asos PLC | 313.50 | 6.63 |
| Rentokil Initial PLC | 350.00 | 5.01 |
| Sainsbury (J) PLC | 256.80 | 3.55 |
| Dr. Martens PLC | 52.80 | 3.53 |
| Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dowlais Group PLC | 51.40 | -6.03 |
| Fresnillo PLC | 1,021.00 | -5.55 |
| Jupiter Fund Management PLC | 69.30 | -5.07 |
| Goodwin PLC | 6,780.00 | -4.51 |
| Spectris PLC | 1,987.00 | -4.38 |
| Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.